IPSEN H1 2023 RESULTS HIGHLIGHTS

FOCUS. TOGETHER. FOR PATIENTS & SOCIETY.

The successful delivery on our strategic roadmap is yielding more top-line growth, advancements in the pipeline and further positive developments from external innovation.

We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions.

I am confident, as we continue to deliver more medicines to patients, in ensuring the sustainable growth of Ipsen.

David Loew

H1 2023 TOTAL SALES



FY 2023 GUIDANCE UPGRADE


Total-sales growth greater than 6.0% (at constant exchange rates)

Core operating margin greater than 30.0% of total sales

KEY FINANCIALS

Core operating income €523m	-7.9%	Free cash flow €371m	+9.6%
Core operating margin 34.0%	-5.6%pts	Core earnings per share ¹ €4.73	-6.6%

GEOGRAPHIC BREAKDOWN H1 2023 TOTAL SALES BY REGION



PIPELINE UPDATE

Onivyde: sNDA accepted (U.S.) in first-line metastatic pancreatic ductal adenocarcinoma

Bylvay: regulatory approval (U.S.): Alagille syndrome

Palovarotene: favorable outcome from U.S. Advisory Committee² meeting (FOP)

Elafibranor: positive top-line data from pivotal ELATIVE Phase III trial

Total-sales growth is at constant exchange rates; all other growth rates are at actual exchange rates. ^{1.} Fully diluted. ²The U.S. FDA Endocrinologic and Metabolic Drugs Advisory Committee. **sNDA**: supplemental New Drug Application; **FOP**: fibrodysplasia ossificans progressiva.

For further information on Ipsen's H1 2023 results and definitions of financial indicators, please refer to the press release at:

www.ipsen.com/investors

Craig Marks

Vice President, Investor Relations +44 7584 349 193 craig.marks@ipsen.com

Nicolas Bogler

Senior Manager, Investor Relations +33 6 52 19 98 92 nicolas.bogler@ipsen.com

